{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:30:39Z","timestamp":1773721839240,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Lymphocytes and their subsets are implicated in both the onset and remission of gout. However, the specific roles in gout recurrence and complete remission remain unclear. This study aimed to characterize lymphocyte immunophenotypes across different stages of gout and developed a predictive model for remission and recurrence of gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Plasma levels of 75 lymphocyte immunophenotypes were determined using multiplex flow cytometry in patients with acute gout flare (AG, n=78), gout remission (RG, n=63), and healthy controls (NC, n=66). Lymphocyte immunophenotyping candidates and significant clinical parameters were subjected to LASSO regression for conducting a predictive model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant variations in lymphocyte profiles were identified among the groups. A combination of T peripheral helper cells, virus-specific cytotoxic natural killer (NK) cells, inhibition of V\u03b41 and V\u03b42 cells, along with BMI, eGFR, hemoglobin, uric acid, distinguished RG from NC (AUC=0.934). Similarly, inhibition of V\u03b42 cells, virus-specific cytotoxic NK cells, inactive and terminally differentiated virus-specific CD8<jats:sup>+<\/jats:sup> T cells, plus hematological parameters, classified RG from AG (AUC = 0.814) and predicted gout recurrence in a one-year follow-up validation cohort (AUC = 0.724). Inhibition of V\u03b42 cells and virus-infected specific cytotoxic NK cells are strongly associated with gout recurrence and complete remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Significant alterations in lymphocyte immunophenotypes, notably the inhibition of V\u03b42 cells and virus-infected specific cytotoxic NK cells during the transition from gout recurrence to complete remission, provide compelling evidence to enhance the clinical delineation of gout stages and propel mechanistic investigations into the progression of gout.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1540429","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:24:15Z","timestamp":1744867455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Delineating circulating lymphocyte subsets in the transition from gout remission to recurrence"],"prefix":"10.3389","volume":"16","author":[{"given":"Hanjie","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.intimp.2023.110466","article-title":"Immune and inflammatory mechanisms and therapeutic targets of gout: An update","volume":"121","author":"Liu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0280-0","article-title":"Defining remission in patients with gout","volume":"15","author":"Bardin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using delphi and 1000Minds consensus exercises","volume":"68","author":"de Lautour","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13075-019-1941-8","article-title":"Concurrent validity of provisional remission criteria for gout: a dual-energy CT study","volume":"21","author":"Dalbeth","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/imr.12833","article-title":"Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemia","volume":"294","author":"Cabau","year":"2020","journal-title":"Immunol Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955806","article-title":"Recent insights into the role of macrophages in acute gout","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"106877","DOI":"10.1016\/j.intimp.2020.106877","article-title":"Role of T cells in the pathogenesis and treatment of gout","volume":"88","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.625458","article-title":"Age-specific imbalance of circulating tfh cell subsets and its association with gout-targeted kidney impairment","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.41173","article-title":"Differential DNA methylation of networked signaling, transcriptional, innate and adaptive immunity, and osteoclastogenesis genes and pathways in gout","volume":"72","author":"Wang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e171417","DOI":"10.1172\/jci.insight.171417","article-title":"Single-cell transcriptomics reveals variations in monocytes and Tregs between gout flare and remission","volume":"8","author":"Yu","year":"2023","journal-title":"JCI Insight"},{"key":"B14","doi-asserted-by":"publisher","first-page":"113139","DOI":"10.1016\/j.celrep.2023.113139","article-title":"MSU crystal deposition contributes to inflammation and immune responses in gout remission","volume":"42","author":"Gu","year":"2023","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e12716","DOI":"10.1111\/acel.2018.17.issue-2","article-title":"T-cell immunoglobulin and ITIM domain contributes to CD8(+) T-cell immunosenescence","volume":"17","author":"Song","year":"2018","journal-title":"Aging Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e159579","DOI":"10.1172\/JCI159579","article-title":"Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia","volume":"132","author":"Rutella","year":"2022","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad201","article-title":"Serum uric acid levels and health outcomes in CKD: a prospective cohort study","volume":"39","author":"Wu","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225761","article-title":"Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout","volume":"83","author":"Tedeschi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.7.1129","article-title":"p46, a novel natural killer cell-specific surface molecule that mediates cell activation","volume":"186","author":"Sivori","year":"1997","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609692104","article-title":"Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46","volume":"104","author":"Walzer","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781","article-title":"Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nri797","article-title":"Gammadelta T cells: functional plasticity and heterogeneity","volume":"2","author":"Carding","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic Vgamma9Vdelta2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2019.01.010","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000861","article-title":"Update on gout management: what is old and what is new","volume":"34","author":"Afinogenova","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.26640","article-title":"Serum urate and recurrent gout","volume":"331","author":"McCormick","year":"2024","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225305","article-title":"Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker","volume":"83","author":"Ea","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S408929","article-title":"Joint application of multiple inflammatory cytokines in diagnosis of gout flare","volume":"16","author":"Yu","year":"2023","journal-title":"J Inflammation Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1540429\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:24:16Z","timestamp":1744867456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1540429\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1540429"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1540429","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"1540429"}}